Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

ABSTRACT: For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

SUBMITTER: Fong Y 

PROVIDER: S-EPMC11797383 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature